<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913091</url>
  </required_header>
  <id_info>
    <org_study_id>18-01183</org_study_id>
    <nct_id>NCT03913091</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine (Exparel 速 ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)</brief_title>
  <official_title>Liposomal Bupivacaine (Exparel 速 ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV , randomized, single-blind, single-center study comparing patient related&#xD;
      outcomes such as postoperative pain and opioid usage for patients who receive ISB 's&#xD;
      containing liposomal bupivacaine (Exparel速) plus 0.5% bupivacaine HCL versus 0.5% bupivacaine&#xD;
      HCL undergoing total shoulder arthroplasty. The objective of this study is to compare opioid&#xD;
      utilization and pain management of patients who receive Exparel in an ISB vs standard 0.5%&#xD;
      bupivacaine HCL during the initial 72 --- hour post --- operative period. Additionally, to&#xD;
      understand the duration of block after addition of Exparel速 to bupivacaine in an Interscalene&#xD;
      block after TSA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">January 19, 2021</completion_date>
  <primary_completion_date type="Actual">January 19, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Utilization</measure>
    <time_frame>72 Post Operative Period</time_frame>
    <description>Measure in morphine milligram equivalents [MME]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain Scores</measure>
    <time_frame>Day 7 Post Operative Period</time_frame>
    <description>Patient reported pain intensity assessment. Patients will be asked 3 questions, with a range of scores of 1-&quot;Had no pain&quot; to 5- &quot;Very Severe.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Shoulder Pain</condition>
  <arm_group>
    <arm_group_label>20 mL 0.5% Bupivacaine HCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interscalene nerve block with Liposomal + Bupivacaine 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered in an Interscalene block for TSA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL</description>
    <arm_group_label>Interscalene nerve block with Liposomal + Bupivacaine 0.5%</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% Bupivacaine HCL</intervention_name>
    <description>0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)</description>
    <arm_group_label>20 mL 0.5% Bupivacaine HCL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing total shoulder arthroplasty;&#xD;
&#xD;
          -  Patients who consent to be randomized.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 and older than 75;&#xD;
&#xD;
          -  Patients with a history of chronic pain that have used opioids for pain management for&#xD;
             3 months or longer;&#xD;
&#xD;
          -  Patients who are allergic to oxycodone;&#xD;
&#xD;
          -  Patients who are unable to speak English;&#xD;
&#xD;
          -  Patients with diagnosed or self---reported cognitive dysfunction;&#xD;
&#xD;
          -  Patients with a history of neurologic disorder that can interfere with pain sensation;&#xD;
&#xD;
          -  Patients with a history of drug or recorded alcohol abuse;&#xD;
&#xD;
          -  Patients who are unable to understand or follow instructions;&#xD;
&#xD;
          -  Patients with severe liver disease, renal insufficiency, congestive heart failure,&#xD;
             and/or significant heart disease;&#xD;
&#xD;
          -  Patients with an allergy or contraindication to any of the medications used in the&#xD;
             study, or patients with a contraindication to any study procedures;&#xD;
&#xD;
          -  Patients with BMI over 40;&#xD;
&#xD;
          -  Any patient that the investigators feel cannot comply with all study related&#xD;
             procedures;&#xD;
&#xD;
          -  NYU Langone Health students, residents, faculty or staff members&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uchenna Umeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Shoulder Arthroplasty (TSA)</keyword>
  <keyword>Interscalene Nerve Block (ISB)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Data will be available to achieve aims in the approved proposal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Immediately following publication. No end date</ipd_time_frame>
    <ipd_access_criteria>Requests should be directed to uchenna.umeh@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.&#xD;
Access will be given to researchers who provide a methodologically sound proposal and investigators whose proposed use of the data has been approved by an independent review committee (&quot;learned intermediary&quot;) identified for this purpose.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

